Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

3.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
3.9K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

63
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
63

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same author

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same author

Molecular lineages of sporadic mismatch-repair deficient colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Computed Quantitative Planar Imaging for Targeted Alpha Therapy: Model-Based Sparse Reconstruction Validated With a Novel <sup>225</sup>Ac Epoxy Phantom.

IEEE transactions on medical imaging·2026
Same author

Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.

Insights into imaging·2026

Related Experiment Video

Updated: May 20, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.4K

Neuroendocrine Tumors: Beta Labeled Radiopeptides.

Lisa Bodei1, Vetri Sudar Jayaprakasam1, Bernadette Zhi Ying Wong2

  • 1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.

PET Clinics
|April 8, 2025
PubMed
Summary
This summary is machine-generated.

Peptide receptor radionuclide therapy (PRRT) uses radiolabeled peptides to target neuroendocrine tumors. Current 177Lu-peptide treatments offer tumor control but require personalized dosimetry for improved efficacy and reduced toxicity.

Keywords:
(177)Lu-DOTATATEIndividualizationPeptide receptor radionuclide therapyTheranostics

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

286
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

11.9K

Related Experiment Videos

Last Updated: May 20, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.4K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

286
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

11.9K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Peptide receptor radionuclide therapy (PRRT) targets somatostatin receptors on neuroendocrine tumor cells using radiolabeled octreotide derivatives.
  • While initially using 90Y-peptides, 177Lu-peptides are now the standard for PRRT.
  • PRRT achieves significant tumor and symptomatic control, but responses are often transient.

Purpose of the Study:

  • To review current strategies for enhancing PRRT efficacy and tolerability.
  • To highlight the importance of personalized treatment approaches in PRRT.
  • To emphasize the role of dosimetry and radiosensitivity assessment.

Main Methods:

  • Administration of radiolabeled octreotide derivatives targeting somatostatin receptors.
  • Utilization of 177Lu-labeled peptides as the predominant therapeutic agent.
  • Focus on individualized treatment planning based on dosimetric estimates.

Main Results:

  • PRRT demonstrates substantial tumor and symptomatic control in neuroendocrine tumor patients.
  • Current therapeutic responses are limited in duration.
  • Ongoing research into novel peptides and strategies aims to improve outcomes.

Conclusions:

  • Personalized PRRT, guided by precise dosimetry for tumors and normal organs, is crucial.
  • Assessing tissue radiosensitivity is a critical factor for optimizing treatment.
  • Further advancements in peptide design and therapeutic strategies are needed to improve long-term efficacy and tolerability.